Physician profile
Parveen B Vora
NPI 1215134689
$2,263.39
in general payments reported to CMS, 2019-2025
19 companies · $125 in 2025
The $125 reported for 2025 was less than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,256 · 2020: $36.15 · 2021: $125 · 2023: $241 · 2024: $480 · 2025: $125.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $846.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $846.22 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $491.71 | 2019-2024 | Tezspire |
| Medtronic Vascular, INC. | $158.63 | 2019 | |
| Pfizer INC. | $152.18 | 2019 | |
| Allergan, INC. | $146.06 | 2019 | |
| Novo Nordisk INC | $144.76 | 2019-2020 | |
| Gilead Sciences, INC. | $140.14 | 2019 | |
| Sanofi Pasteur INC. | $136.76 | 2019-2025 | |
| Lilly USA, LLC | $131.65 | 2019 | |
| Incyte Corporation | $124.99 | 2021 | |
| Regeneron Healthcare Solutions, INC. | $120.79 | 2023 | Dupixent |
| Glaxosmithkline, LLC. | $120.43 | 2024 | Nucala |
| Sanofi-Aventis U.S. LLC | $109.40 | 2019 | |
| Merck Sharp & Dohme LLC | $79.52 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $59.96 | 2019-2020 | |
| Janssen Pharmaceuticals, INC | $54.42 | 2019 |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $38.75 | 2019 | |
| Osiris Therapeutics INC. | $21.48 | 2019 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $16.33 | 2019 | |
| Depuy Synthes Sales INC. | $15.43 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Parveen Vora listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.